Feed ILMN
IL

Illumina

ILMN · NASDAQ

$270.00 -0.79% (-$2.16)
1M +25.24%
Market Cap $41.4B
P/E Ratio 50.23x
Div. Yield -
ROE 31.08%

Bulios Fair Price

$250.38

7.3% downside

Current Price

$270

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ILMN is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Moderate
6/9
Valuation
5 /100
Expensive
P/FCF 44.13x
P/E 50.23x
P/B 14.60x
Growth
41 /100
Stable
Book val. growth 25.55%
Rev. growth 1.82%
FCF growth 106.32%
Profitability
96 /100
Strong
Op. margin 20.97%
Gross margin 66.79%
FCF margin 20.90%
Quality
83 /100
Excellent
ROA 12.41%
ROIC 13.54%
Asset turnover 0.68x
Debt
80 /100
Low
Int. coverage 14.53x
Debt/Equity 0.89x
Net debt/EBITDA 1.09x
Stability
42 /100
Moderate
EPS volatility 87.91%
Beta 1.47x
Profitable years 1

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ILMN
Online

About the company

Illumina Inc. (ILMN) is an American biotechnology company specializing in the development and production of DNA sequencing and genetic analysis systems. With innovative products and technologies such as the NovaSeq sequencer, Illumina enables researchers and clinicians to conduct advanced genetic studies and diagnostics. The company is known for its emphasis on innovation and research, allowing it to continuously improve its products and expand the possibilities of genetic research. Illumina also collaborates with academic and industrial partners to develop new applications for genetic analysis. Illumina Inc. (ILMN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on genetics and innovations in DNA sequencing.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Jacob Thaysen

Employees

8,600

Headquarters

San Diego

Upcoming events

29 OCT

Earnings

Upcoming earnings report

32d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.